Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview

News provided by

Generex Biotechnology Corporation

Jan 17, 2013, 09:45 ET

WORCESTER, Mass. and TORONTO, Jan. 17, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that the AE37 breast cancer vaccine under development by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has been featured in a Micro-Cap Review interview of Antigen Express President Dr. Eric von Hofe, PhD conducted earlier this month at the JPMorgan Healthcare Conference in San Francisco.

The interview covers the status of the Antigen Express lead compound AE37 and the distinguishing features of the Company in the field of cancer immunotherapy. The Company is currently nearing the end of a randomized, controlled and blinded Phase II trial designed to test the ability of AE37 to prevent relapse in patients who have had breast cancer. Interim data from the trial show a strong trend toward decreased relapse in patients who have received the vaccine. Based upon these results the FDA has given the Company the green light to proceed with submission of a Phase III protocol.  

The interview is available for viewing online:

SNN Incorporated publishes the Micro-Cap Review print & web magazine, www.stocknewsnow.com financial portal, the Ask Mr. Wallstreet newsletter, www.SNNwire.com & the Patent Pending, SNN Video Press Release, VPR™. SNN owns and operates the SNNLive TV show & the SNN StockUmentary TV show, and StockNewsNow Radio with Gary McKenzie.  StockNewsNow.com is a Micro-Cap financial portal that features SNNLive CEO Video Interviews, the Micro-Cap Review Magazine, S&P Capital IQ Stock Reports, StockNewsNow Radio, Wall Street Views, and Real-Time News from the financial markets.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED